Lunai Bioworks (NASDAQ: LNAI) Launches National Chemical Defense Consortium Targeting $400M-$1.2B U.S. Countermeasure Programs; 3-Year AI Antidote Development Model
PR Newswire —
AI platform integrates academic and defense research to accelerate rapid antidote discovery and federal stockpiling for emerging chemical threats. SACRAMENTO, Calif., March 19, 2026 /PRNewswire/ -- Lunai Bioworks (NASDAQ: LNAI), through its wholly owned subsidiary BioSymetrics, today...